Non-inferiority Trial of Two Snake Antivenoms in CAR (PAVES)

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Snake Bites
Interventions
BIOLOGICAL

FAV-Africa

Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.

BIOLOGICAL

EchiTabPlus-ICP

Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Medecins Sans Frontieres, Netherlands

OTHER

lead

Epicentre

OTHER

NCT02694952 - Non-inferiority Trial of Two Snake Antivenoms in CAR (PAVES) | Biotech Hunter | Biotech Hunter